芳香化酶抑制剂联合重组人生长激素治疗青春期大骨龄矮身材男童的研究进展  

Research progress of aromatase inhibitor combined with recombinant human growth hormone in the treatment of adolescent boys with large bone age and short stature

作　　者：周园 徐庄剑[1] 赵金玲 马亚萍[1] ZHOU Yuan;XU Zhuangjian;ZHAO Jinling;MA Yaping(Department of Paediatrics,Affiliated Hospital of Jiangnan University,Jiangsu,Wuxi 214122,China)

机构地区：[1]江南大学附属医院儿科,江苏无锡214122

出　　处：《中国医药科学》2024年第20期29-32,65,共5页China Medicine And Pharmacy

基　　金：江苏省妇幼健康科研项目重点资助项目(F202117);江苏省无锡市卫生健康“三名”战略人才项目(第二届“双百”中青年医疗卫生拔尖人才)(BJ2023054)。

摘　　要：青春期大骨龄矮身材男童骨骺剩余生长空间有限、预测成年身高矮小,传统治疗方案对身高的改善效果不理想。因而,帮助这类患儿达到正常或目标身高的治疗更具有挑战性。近年来,芳香化酶抑制剂联合重组人生长激素治疗方案对于增加青春期大骨龄矮身材男童的身高方面已显示出一定成效,且在接受治疗期间并未出现严重不良反应。本研究在分析芳香化酶抑制剂作用机制的基础上,从单独来曲唑或阿那曲唑以及其与重组人生长激素联合治疗青春期大骨龄矮身材男童身高的有效性和安全性展开综述,以期为该类患儿的治疗开辟新思路,并为该病临床治疗方案的制订和完善提供有价值的参考。With limited remaining epiphyseal growth space in adolescent boys with large bone age and short stature and predicted short adult height,traditional treatment plans are not as effective in improving height.Consequently,treating such children to achieve normal or target height is more challenging.In recent years,the combination of aromatase inhibitors and recombinant human growth hormone therapy has shown some effectiveness in increasing the height of adolescents with large bone age and short stature,and there have been no serious adverse reactions during treatment.On the basis of analyzing the mechanism of action of aromatase inhibitors,this study provides a review of the effectiveness and safety of using letrozole alone or anastrozole in combination with recombinant human growth hormone to treat height in adolescent boys with large bone age and short stature.The aim is to open up new ideas for the treatment of this type of child and provide valuable references for the formulation and improvement of clinical treatment plans for this disease.

关 键 词：来曲唑 阿那曲唑 重组人生长激素 青春期大骨龄 矮身材 男童 综述 

分 类 号：R725.8[医药卫生—儿科]